Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 inter alia to consider and approve a) The Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2025 along with the Statement of Assets and Liabilities Cash Flow Statement and take note of the Audit Report with modified opinion if any thereon.b) The Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31 2025 andc) Recommend the Final Dividend if any for the financial year ended March 31 2025